Avita Medical Inc. (NASDAQ:RCEL – Get Free Report)’s share price rose 4.6% during trading on Tuesday. The stock traded as high as $15.84 and last traded at $15.92. 40,973 shares changed hands during trading, a decline of 88% from the average daily volume of 344,605 shares. The stock had previously closed at $15.22.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on the company. BTIG Research boosted their target price on Avita Medical from $15.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, November 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Lake Street Capital lifted their target price on Avita Medical from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Wall Street Zen upgraded shares of Avita Medical from a “hold” rating to a “buy” rating in a research note on Saturday, November 14th. Finally, TD Cowen boosted their price target on shares of Avita Medical from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, November 12th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Avita Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.
Read Our Latest Stock Analysis on Avita Medical
Avita Medical Trading Up 6.7%
The business’s fifty day simple moving average is $13.72 and its two-hundred day simple moving average is $7.33. The stock has a market capitalization of $528.80 million, a P/E ratio of -14.26 and a beta of 2.03.
Avita Medical (NASDAQ:RCEL – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. The business had revenue of $26.11 million during the quarter, compared to the consensus estimate of $22.35 million. On average, equities research analysts anticipate that Avita Medical Inc. will post -0.94 earnings per share for the current year.
Institutional Investors Weigh In On Avita Medical
Large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP lifted its holdings in shares of Avita Medical by 107.1% during the third quarter. Marshall Wace LLP now owns 700,745 shares of the company’s stock valued at $8,220,000 after purchasing an additional 362,358 shares in the last quarter. BlackRock Inc. purchased a new stake in Avita Medical in the 2nd quarter worth approximately $2,333,000. Goldman Sachs Group Inc. boosted its stake in shares of Avita Medical by 247.4% in the third quarter. Goldman Sachs Group Inc. now owns 266,595 shares of the company’s stock worth $3,127,000 after acquiring an additional 189,858 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Avita Medical by 71.4% in the 2nd quarter. NewEdge Advisors LLC now owns 148,931 shares of the company’s stock valued at $615,000 after purchasing an additional 62,046 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Avita Medical by 145.3% in the first quarter. Bank of America Corp DE now owns 62,128 shares of the company’s stock valued at $230,000 after purchasing an additional 36,799 shares in the last quarter. Institutional investors own 27.66% of the company’s stock.
About Avita Medical
AVITA Medical is a regenerative medicine company focused on treatments for skin restoration. Its flagship technology, the RECELL System, enables clinicians to use a small sample of a patient’s healthy skin to prepare a suspension of skin cells for application to wounds. The company’s RECELL products are used in the treatment of burns and certain other skin injuries, including full-thickness skin defects. The approach is intended to support wound coverage while reducing the amount of donor skin needed compared with conventional skin-grafting procedures.
Featured Stories
- Five stocks we like better than Avita Medical
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Receive News & Ratings for Avita Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avita Medical and related companies with MarketBeat.com's FREE daily email newsletter.
